Skip to main content
Article thumbnail
Location of Repository

STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response

By Lan-Sun Chen, Pei-Chi Wei, Taming Liu, Chung-Hsuan Kao, Li-Mei Pai and Chien-Kuo Lee


Interferons (IFNs) are key regulators for both innate and adaptive immune responses. By screening ENU-mutagenized mice, we identified a pedigree- P117 which displayed impaired response to type I, but not type II, IFNs. Through inheritance test, genetic mapping and sequencing, we found a T to A point mutation in the 5' splice site of STAT2 intron 4–5, leading to cryptic splicing and frame shifting. As a result, the expression of STAT2 protein was greatly diminished in the mutant mice. Nonetheless, a trace amount of functional STAT2 protein was still detectable and was capable of inducing, though to a lesser extent, IFNα-downstream gene expressions, suggesting that P117 is a STAT2 hypomorphic mutant. The restoration of mouse or human STAT2 gene in P117 MEFs rescued the response to IFNα, suggesting that the mutation in STAT2 is most likely the cause of the phenotypes seen in the pedigree. Development of different subsets of lymphocytes appeared to be normal in the mutant mice except that the percentage and basal expression of CD86 in splenic pDC and cDC were reduced. In addition, in vitro Flt3L-dependent DC development and TLR ligand-mediated DC differentiation were also defective in mutant cells. These results suggest that STAT2 positively regulates DC development and differentiation. Interestingly, a severe impairment of antiviral state and increased susceptibility to EMCV infection were observed in the mutant MEFs and mice, respectively, suggesting that the remaining STAT2 is not sufficient to confer antiviral response. In sum, the new allele of STAT2 mutant reported here reveals a role of STAT2 for DC development and a threshold requirement for full functions of type I IFNs

Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1997). Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA
  2. (2008). BR: Interferon-inducible antiviral effectors. Nat Rev Immunol
  3. (2007). Bream JH: IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol
  4. (2006). CC: ENU-mutagenesis: insight into immune function and pathology. Curr Opin Immunol
  5. (2006). CK: STAT3 positively regulates an early step in B-cell development. Blood
  6. (2002). CK: What does Stat3 do?
  7. (2000). CR: Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood
  8. (1999). DE: Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes. J Exp Med
  9. (1999). DE: Stat protein transactivation domains recruit p300/CBP through widely divergent sequences.
  10. (2002). DE: STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity
  11. (1996). DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell
  12. (1998). Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7.
  13. (2000). Distinct requirements for IFNs and STAT1 in NK cell function.
  14. (1998). DR: Efficient localization by internal haplotype analysis. Mammalian Genome
  15. (2004). Hogenesch JB: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA
  16. (1997). JC: Cellular responses to interferon-gamma. Annu Rev Immunol
  17. (2005). JD: IL-12, but not IFN-alpha, promotes STAT4 activation and Th1 development in murine CD4+ T cells expressing a chimeric murine/human Stat2 gene.
  18. (2000). KM: Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol
  19. (2007). Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol
  20. (2007). Liu YJ: Development of dendritic-cell lineages. Immunity
  21. (2006). Medzhitov R: Type I interferons in host defense. Immunity
  22. (2007). MG: Flt3 in regulation of type I interferon-producing cell and dendritic cell development.
  23. (2000). MJ: Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains. Genesis
  24. (1999). Murine Stat2 is uncharacteristically divergent. Nucleic Acids Res
  25. (1999). Natural adjuvants: endogenous activators of dendritic cells. Nat Med
  26. (2005). Oldstone MB: Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity
  27. (1998). Positive feedback regulation of type I IFN genes by the IFNinducible transcription factor IRF-7. FEBS Lett
  28. (2003). RA: STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity
  29. (2006). RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol
  30. (1996). RD: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell
  31. (2008). SD: ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet
  32. (2007). T: JAK-STAT signaling: from interferons to cytokines.
  33. (2000). Taniguchi T: Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science
  34. (2002). Tough DF: Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood
  35. (2005). Trinchieri G: Type I interferon dependence of plasmacytoid dendritic cell activation and migration.
  36. (1998). Type I IFNs enhance the terminal differentiation of dendritic cells.
  37. (2005). Zhang JJ: Stat1-dependent synergistic activation of Tbet for IgG2a production during early stage of B cell activation.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.